Pablo Olivera1, Linda Thiriet, Amandine Luc, Cedric Baumann, Silvio Danese, Laurent Peyrin-Biroulet. 1. *INSERM U954 and Department of Hepatogastroenterology, Nancy University Hospital, Université de Lorraine, Vandoeuvre-lès-Nancy, France; †ESPRI-BioBase Unit, PARC Clinical Research Support Facility, Nancy University Hospital, Nancy, France; and ‡Humanitas University, IBD Center, Milan, Italy.
Abstract
BACKGROUND: Infliximab (IFX) and adalimumab (ADA) are widely used in the treatment of patients with Crohn's disease (CD). There are few published data on the treatment persistence of IFX and ADA in patients with CD. METHODS: We aimed to compare the persistence rates of IFX versus ADA as first- and second-line tumor necrosis factor antagonist (anti-TNF), to identify factors potentially associated with persistence, and to evaluate reasons for treatment withdrawal in CD patients. We performed a retrospective, single-center cohort study of CD patients treated with IFX or ADA for at least 6 months between June 2002 and May 2016. RESULTS: The median duration of follow-up was 5.4 years. For first-line anti-TNF agent, data on 487 patients with CD were analyzed. The mean (SD) duration of persistence was 3.6 (3.1) years and 2.5 (2.0) years in the IFX and ADA subgroups, respectively; the intergroup difference was not significant (P = 0.219). Factors associated with lower persistence were female sex (P = 0.0005) and stricturing behavior (P = 0.008). For second-line anti-TNF agent, data on 134 patients were analyzed. The mean (SD) duration of persistence was 2.4 (1.9) years and 2.6 (2.1) years in the IFX and ADA subgroups, respectively; again, the intergroup difference was not significant (P = 0.488). Age under 37.2 was the only factor associated with lower persistence (P = 0.016) for second-line treatment with an anti-TNF agent. CONCLUSIONS: IFX and ADA show similar levels of persistence as first- and second-line anti-TNF treatments. Female sex and stricturing behavior were associated with poor persistence of first-line treatments, whereas age was the only factor associated with poor persistence of second-line treatments.
BACKGROUND:Infliximab (IFX) and adalimumab (ADA) are widely used in the treatment of patients with Crohn's disease (CD). There are few published data on the treatment persistence of IFX and ADA in patients with CD. METHODS: We aimed to compare the persistence rates of IFX versus ADA as first- and second-line tumor necrosis factor antagonist (anti-TNF), to identify factors potentially associated with persistence, and to evaluate reasons for treatment withdrawal in CDpatients. We performed a retrospective, single-center cohort study of CDpatients treated with IFX or ADA for at least 6 months between June 2002 and May 2016. RESULTS: The median duration of follow-up was 5.4 years. For first-line anti-TNF agent, data on 487 patients with CD were analyzed. The mean (SD) duration of persistence was 3.6 (3.1) years and 2.5 (2.0) years in the IFX and ADA subgroups, respectively; the intergroup difference was not significant (P = 0.219). Factors associated with lower persistence were female sex (P = 0.0005) and stricturing behavior (P = 0.008). For second-line anti-TNF agent, data on 134 patients were analyzed. The mean (SD) duration of persistence was 2.4 (1.9) years and 2.6 (2.1) years in the IFX and ADA subgroups, respectively; again, the intergroup difference was not significant (P = 0.488). Age under 37.2 was the only factor associated with lower persistence (P = 0.016) for second-line treatment with an anti-TNF agent. CONCLUSIONS:IFX and ADA show similar levels of persistence as first- and second-line anti-TNF treatments. Female sex and stricturing behavior were associated with poor persistence of first-line treatments, whereas age was the only factor associated with poor persistence of second-line treatments.
Authors: Johannes P D Schultheiss; Remi Mahmoud; Jonas M Louwers; Michiel T van der Kaaij; Boris P van Hellemondt; Petra G van Boeckel; Nofel Mahmmod; Bindia Jharap; Herma H Fidder; Bas Oldenburg Journal: Aliment Pharmacol Ther Date: 2021-09-24 Impact factor: 9.524
Authors: Laura Mühl; Emily Becker; Tanja M Müller; Raja Atreya; Imke Atreya; Markus F Neurath; Sebastian Zundler Journal: BMC Gastroenterol Date: 2021-01-22 Impact factor: 3.067